This study beautifully bridges the Nobel-Prize discovery of Tregs with next-gen brain tumor immunotherapy — turning immune brakes into powerful therapeutic levers.
🔗 cell.com/immunity/fulltext/S1074-7613(25)00162-1
This study beautifully bridges the Nobel-Prize discovery of Tregs with next-gen brain tumor immunotherapy — turning immune brakes into powerful therapeutic levers.
🔗 cell.com/immunity/fulltext/S1074-7613(25)00162-1
These same macrophages amplify the power of tumor-targeting antibodies like anti-EGFRvIII, linking adaptive and innate immunity for stronger tumor control.
These same macrophages amplify the power of tumor-targeting antibodies like anti-EGFRvIII, linking adaptive and innate immunity for stronger tumor control.
Without Tregs, monocyte-derived macrophages take the stage — eliminating Tregs via ADCC/ADCP and helping clear tumor cells in an antibody-dependent way.
Without Tregs, monocyte-derived macrophages take the stage — eliminating Tregs via ADCC/ADCP and helping clear tumor cells in an antibody-dependent way.
Using a non-IL-2-blocking anti-CD25 antibody, they cut off IL-2 — Tregs’ fuel — while freeing it for CD8⁺ T cells. This shift activates phagocytic myeloid cells and boosts immune attack.
Using a non-IL-2-blocking anti-CD25 antibody, they cut off IL-2 — Tregs’ fuel — while freeing it for CD8⁺ T cells. This shift activates phagocytic myeloid cells and boosts immune attack.
braintumourireland.com
stophersentumoren.nl
brainstrust.org.uk
www.thebraintumourcharity.org
artc-asso.fr www.thebraintumourcharity.org/living-with-...
braintumourireland.com
stophersentumoren.nl
brainstrust.org.uk
www.thebraintumourcharity.org
artc-asso.fr www.thebraintumourcharity.org/living-with-...